全文获取类型
收费全文 | 157篇 |
免费 | 7篇 |
专业分类
儿科学 | 16篇 |
妇产科学 | 2篇 |
基础医学 | 55篇 |
临床医学 | 18篇 |
内科学 | 26篇 |
神经病学 | 4篇 |
特种医学 | 4篇 |
外科学 | 8篇 |
预防医学 | 10篇 |
眼科学 | 2篇 |
药学 | 2篇 |
肿瘤学 | 17篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 3篇 |
2014年 | 5篇 |
2013年 | 9篇 |
2012年 | 13篇 |
2011年 | 14篇 |
2010年 | 10篇 |
2009年 | 14篇 |
2008年 | 15篇 |
2007年 | 6篇 |
2006年 | 11篇 |
2005年 | 10篇 |
2004年 | 4篇 |
2003年 | 5篇 |
2002年 | 7篇 |
2001年 | 5篇 |
2000年 | 3篇 |
1999年 | 5篇 |
1998年 | 2篇 |
1996年 | 1篇 |
1989年 | 3篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1942年 | 1篇 |
1922年 | 2篇 |
1920年 | 1篇 |
1919年 | 1篇 |
排序方式: 共有164条查询结果,搜索用时 15 毫秒
61.
Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period 总被引:8,自引:0,他引:8
van Adelsberg J Philip G Pedinoff AJ Meltzer EO Ratner PH Menten J Reiss TF;Montelukast Fall Rhinitis Study Group 《Allergy》2003,58(12):1268-1276
BACKGROUND: Proinflammatory mediators such as the cysteinyl leukotrienes are important in the pathophysiology of allergic rhinitis. This study evaluated the efficacy and tolerability of montelukast, a cysteinyl leukotriene receptor antagonist, given once daily in the morning for treatment of seasonal (fall) allergic rhinitis for 4 weeks. METHODS: This was a randomized, double-blind trial with a placebo run-in and a 4-week treatment period. Patients (n = 1079) with a history of allergic rhinitis and a positive skin test to seasonal pollen allergens were assigned to placebo, montelukast 10 mg, or loratadine 10 mg. Symptoms were assessed with a daily diary. RESULTS: Montelukast was more effective than placebo in improving scores for the primary endpoint of daytime nasal symptoms (P = 0.003) and the secondary endpoints of night-time, composite, and daytime eye symptoms, patient's and physician's global evaluations of allergic rhinitis, and rhinoconjunctivitis quality-of-life (P = 0.006). The positive control loratadine also improved scores for the primary endpoint (P = 0.001) and the majority of the secondary endpoints (P < 0.03). When analyzed by week, the treatment effect of montelukast was more persistent than loratadine over all 4 weeks of treatment. CONCLUSION: Montelukast provided effective relief of seasonal allergic rhinitis symptoms when given once daily in the morning, showed significant and sustained improvement in symptoms of allergic rhinitis over 4 weeks of treatment, and was well-tolerated. 相似文献
62.
Steven?SimoensEmail author Betty?Kutten Emmanuel?Keirse Paul?Vanden?Berghe Claire?Beguin Marianne?Desmedt Myriam?Deveugele Christian?Léonard Dominique?Paulus Johan?Menten 《The European journal of health economics》2013,14(3):407-413
Policy makers and health care payers are concerned about the costs of treating terminal patients. This study was done to measure the costs of treating terminal patients during the final month of life in a sample of Belgian nursing homes from the health care payer perspective. Also, this study compares the costs of palliative care with those of usual care. This multicenter, retrospective cohort study enrolled terminal patients from a representative sample of nursing homes. Health care costs included fixed nursing home costs, medical fees, pharmacy charges, other charges, and eventual hospitalization costs. Data sources consisted of accountancy and invoice data. The analysis calculated costs per patient during the final month of life at 2007/2008 prices. Nineteen nursing homes participated in the study, generating a total of 181 patients. Total mean nursing home costs amounted to 3,243 € per patient during the final month of life. Total mean nursing home costs per patient of 3,822 € for patients receiving usual care were higher than costs of 2,456 € for patients receiving palliative care (p = 0.068). Higher costs of usual care were driven by higher hospitalization costs (p < 0.001). This study suggests that palliative care models in nursing homes need to be supported because such care models appear to be less expensive than usual care and because such care models are likely to better reflect the needs of terminal patients. 相似文献
63.
Tang Maoxing Boel Annekatrien Castelluccio Noemi Cardona Barberán Arantxa Christodoulaki Antonia Bekaert Bieke Popovic Mina Vanden Meerschaut Frauke De Sutter Petra Menten Björn Symoens Sofie Vanlander Arnaud V. Stoop Dominic Coucke Paul J. Heindryckx Björn 《Journal of assisted reproduction and genetics》2022,39(3):609-618
Journal of Assisted Reproduction and Genetics - Providing additional insights on the efficacy of human nuclear transfer (NT). Here, and earlier, NT has been applied to minimize transmission risk of... 相似文献
64.
65.
66.
Marianne S Desmedt Yolande L de la Kethulle Myriam I Deveugele Emmanuel A Keirse Dominique J Paulus Johan J Menten Steven R Simoens Paul J vanden Berghe Claire M Beguin 《BMC palliative care》2011,10(1):2
Background
Hospital care plays a major role at the end-of-life. But little is known about the overall size and characteristics of the palliative inpatient population. The aim of our study was to analyse these aspects. 相似文献67.
68.
Paul M.J. Clement Benoit Beuselinck Karen Van Beek P. Georgette Mertens Paul Cornelissen Johan Menten 《Case reports in oncology》2013,6(1):169-173
Pain is a prevalent condition in patients with cancer, particularly in advanced stages of cancer. Although strong opioids are the mainstay of cancer pain management protocols, patients are often undertreated. Transdermal buprenorphine is currently available for the treatment of moderate to severe cancer pain and severe pain which does not respond to nonopioid analgesics; patch doses of 35, 52.5 and 70 µg/h are available (applied for up to 96 h), with no more than 2 transdermal patches at the same time, regardless of the strength. To date, there are no published reports in the literature of the use of high-dose transdermal buprenorphine (>140 µg/h). Herein, we present 2 cases of palliative cancer patients who received transdermal buprenorphine at doses titrated up to 210 and 175 µg/h, respectively, for the management of pain. Transdermal buprenorphine titrated to doses >140 µg/h provided adequate pain control and was well tolerated. Future studies to confirm these initial observations are warranted.Key words: Cancer pain, Palliative cancer, Transdermal buprenorphine 相似文献
69.
70.